EA201100424A1 - Новые ингибиторы - Google Patents
Новые ингибиторыInfo
- Publication number
- EA201100424A1 EA201100424A1 EA201100424A EA201100424A EA201100424A1 EA 201100424 A1 EA201100424 A1 EA 201100424A1 EA 201100424 A EA201100424 A EA 201100424A EA 201100424 A EA201100424 A EA 201100424A EA 201100424 A1 EA201100424 A1 EA 201100424A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- new inhibitors
- glutaminyl cyclase
- inhibitors
- modulating
- context
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Abstract
В заявке описаны соединения общей формулы (I)где R, R, R, R, Х и Y определены в данном контексте, в качестве ингибиторов глутаминилциклазы и, следовательно, их применение для лечения состояний, которые можно лечить при модуляции активности глутаминилциклазы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9411808P | 2008-09-04 | 2008-09-04 | |
PCT/EP2009/061453 WO2010026212A1 (en) | 2008-09-04 | 2009-09-04 | Novel inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100424A1 true EA201100424A1 (ru) | 2011-10-31 |
EA021150B1 EA021150B1 (ru) | 2015-04-30 |
Family
ID=41278686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100424A EA021150B1 (ru) | 2008-09-04 | 2009-09-04 | Производные имидазолидина в качестве ингибиторов глутаминилциклазы |
Country Status (17)
Country | Link |
---|---|
US (1) | US8962860B2 (ru) |
EP (1) | EP2344157B1 (ru) |
JP (1) | JP5707327B2 (ru) |
KR (1) | KR101694556B1 (ru) |
CN (1) | CN102186475B (ru) |
AU (1) | AU2009289238B2 (ru) |
BR (1) | BRPI0918564B1 (ru) |
CA (1) | CA2735795C (ru) |
DK (1) | DK2344157T3 (ru) |
EA (1) | EA021150B1 (ru) |
ES (1) | ES2599621T3 (ru) |
IL (1) | IL211018A (ru) |
MX (1) | MX2011002106A (ru) |
NZ (1) | NZ591531A (ru) |
SG (1) | SG193828A1 (ru) |
WO (1) | WO2010026212A1 (ru) |
ZA (1) | ZA201100898B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5788320B2 (ja) * | 2008-09-04 | 2015-09-30 | プロビオドルグ エージー | イソqc阻害剤の使用 |
KR101755737B1 (ko) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체 |
WO2011076854A1 (en) | 2009-12-22 | 2011-06-30 | Probiodrug Ag | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
ES2570167T3 (es) * | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
JP2014515364A (ja) * | 2011-05-27 | 2014-06-30 | プロビオドルグ エージー | 放射能標識グルタミニルシクラーゼ阻害剤 |
CN105263927B (zh) * | 2013-03-15 | 2019-03-15 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂 |
WO2016097305A1 (en) | 2014-12-19 | 2016-06-23 | Probiodrug Ag | Novel method for the detection of pglu-abeta peptides |
CN108658869A (zh) * | 2017-03-29 | 2018-10-16 | 复旦大学 | 具有抗肿瘤活性的化合物及其制备方法和在制药中的用途 |
RU2665633C1 (ru) * | 2017-05-26 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Новый ингибитор глутаминилциклаз и его применение |
RU2662559C1 (ru) * | 2017-10-27 | 2018-07-26 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
AU2019223215B2 (en) | 2018-02-23 | 2022-09-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases |
TWI715156B (zh) | 2018-08-31 | 2021-01-01 | 財團法人國家衛生研究院 | 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途 |
WO2020242933A1 (en) * | 2019-05-24 | 2020-12-03 | Emory University | Asparagine endopeptidase (aep) inhibitors, compositions, and uses related thereto |
EP4359405A1 (en) * | 2021-06-24 | 2024-05-01 | Insilico Medicine IP Limited | Beta-lactam derivatives for the treatment of diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD293584A5 (de) * | 1990-03-23 | 1991-09-05 | Adw,Zi Fuer Organische Chemie,De | Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen |
DE4320432A1 (de) * | 1993-06-21 | 1994-12-22 | Bayer Ag | Substituierte Mono- und Bipyridylmethylderivate |
US20040006011A1 (en) * | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
WO1999006361A2 (en) | 1997-07-31 | 1999-02-11 | Abbott Laboratories | N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
EP1620091B1 (en) * | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP4996926B2 (ja) * | 2004-02-05 | 2012-08-08 | プロビオドルグ エージー | グルタミニルシクラーゼの新規の阻害剤 |
US7795287B2 (en) | 2006-09-01 | 2010-09-14 | Allergan, Inc. | Therapeutic substituted hydantoins and related compounds |
NZ590631A (en) * | 2006-09-21 | 2011-12-22 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
EP2091945B1 (en) * | 2006-11-09 | 2014-01-15 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
CN101519376B (zh) * | 2008-02-27 | 2012-10-10 | 上海药明康德新药开发有限公司 | 一种芳香环双酰胺螺环类药物模板的合成方法 |
JP5788320B2 (ja) * | 2008-09-04 | 2015-09-30 | プロビオドルグ エージー | イソqc阻害剤の使用 |
-
2009
- 2009-09-04 EP EP09782605.1A patent/EP2344157B1/en active Active
- 2009-09-04 EA EA201100424A patent/EA021150B1/ru not_active IP Right Cessation
- 2009-09-04 KR KR1020117007403A patent/KR101694556B1/ko active IP Right Grant
- 2009-09-04 DK DK09782605.1T patent/DK2344157T3/en active
- 2009-09-04 ES ES09782605.1T patent/ES2599621T3/es active Active
- 2009-09-04 CA CA2735795A patent/CA2735795C/en active Active
- 2009-09-04 JP JP2011525556A patent/JP5707327B2/ja active Active
- 2009-09-04 AU AU2009289238A patent/AU2009289238B2/en active Active
- 2009-09-04 CN CN200980139148.0A patent/CN102186475B/zh active Active
- 2009-09-04 NZ NZ591531A patent/NZ591531A/en unknown
- 2009-09-04 MX MX2011002106A patent/MX2011002106A/es active IP Right Grant
- 2009-09-04 SG SG2013064738A patent/SG193828A1/en unknown
- 2009-09-04 BR BRPI0918564-0A patent/BRPI0918564B1/pt active IP Right Grant
- 2009-09-04 WO PCT/EP2009/061453 patent/WO2010026212A1/en active Application Filing
- 2009-09-04 US US12/554,611 patent/US8962860B2/en active Active
-
2011
- 2011-02-02 IL IL211018A patent/IL211018A/en active IP Right Grant
- 2011-02-03 ZA ZA2011/00898A patent/ZA201100898B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA021150B1 (ru) | 2015-04-30 |
EP2344157A1 (en) | 2011-07-20 |
JP5707327B2 (ja) | 2015-04-30 |
AU2009289238B2 (en) | 2014-09-04 |
US20100119475A1 (en) | 2010-05-13 |
KR20110074975A (ko) | 2011-07-05 |
NZ591531A (en) | 2012-03-30 |
ZA201100898B (en) | 2012-02-29 |
BRPI0918564B1 (pt) | 2023-11-28 |
IL211018A (en) | 2015-11-30 |
SG193828A1 (en) | 2013-10-30 |
DK2344157T3 (en) | 2016-09-05 |
CN102186475A (zh) | 2011-09-14 |
US8962860B2 (en) | 2015-02-24 |
AU2009289238A1 (en) | 2010-03-11 |
CA2735795C (en) | 2018-02-20 |
CN102186475B (zh) | 2016-08-03 |
EP2344157B1 (en) | 2016-05-25 |
JP2012502006A (ja) | 2012-01-26 |
CA2735795A1 (en) | 2010-03-11 |
WO2010026212A1 (en) | 2010-03-11 |
BRPI0918564A2 (pt) | 2015-12-01 |
ES2599621T3 (es) | 2017-02-02 |
KR101694556B1 (ko) | 2017-01-09 |
IL211018A0 (en) | 2011-04-28 |
MX2011002106A (es) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100424A1 (ru) | Новые ингибиторы | |
EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
EA201170521A1 (ru) | Новые соединения | |
EA201200951A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
EA201100447A1 (ru) | Органические соединения | |
EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA201100037A1 (ru) | Органические соединения | |
EA201790882A1 (ru) | Способы и композиции для терапии рака печени | |
EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
EA201201648A1 (ru) | Стимуляторы sgc | |
EA201290880A1 (ru) | Новые соединения - ингибиторы фермента | |
EA201000100A1 (ru) | Гетероциклические соединения, полезные в качестве ингибиторов mk2 | |
MX336381B (es) | Boronatos como inhibidores de arginasa. | |
EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
EA201391626A1 (ru) | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака | |
EA201100125A1 (ru) | Производные пирролопиридинилпиримидин-2-иламина | |
EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
EA200901653A1 (ru) | ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC | |
EA201170051A1 (ru) | Гетероциклическое соединение и его применение | |
MX2009001494A (es) | 2-aminobenzoxazol carboxamidas como moduladores 5ht3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
TC4A | Change in name of a patent proprietor in a eurasian patent | ||
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title |